공고 • May 15
Microba Life Sciences Limited Announces Landmark GI Study Results from over 4,600 Patients
Microba Life Sciences Limited announced preliminary results from the analysis of over 4,600 MetaXplore GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often go undetected by conventional testing. In over 70% of cases, the test revealed findings, such as abnormalities in gut bacteria, signs of infection, markers of inflammation or insufficiency that could inform targeted treatment strategies. Further, two-thirds of MetaXplore patients in a separate study of follow up survey results reported improvement of symptoms after their care was guided by the test results. These results highlight the clinical value of MetaXplore test results in advancing outcomes for patients with chronic lower gastrointestinal disorders, highlighting the potential to reshape clinical management of these conditions and set a new standard of care. An in-depth analysis of billing and claims data for MetaXplore target patient populations, has estimated an addressable population of 82.2 million patients across US, Germany, Italy, Spain, France, United Kingdom and Australia. Analysis conducted by Microba of 4,616 MetaXplore™?GI Plus patients test results from Australia revealed that 71.4% (3,295) of reports identified actionable results. 41.9% (1,932) of reports showed abnormal microbiome markers linked to gastrointestinal health, including 7% that were positive for a pathogen species that can cause GI infection. 9.9% (459) of reports tested positive for a gastrointestinal marker (e.g. inflammation, pancreatic insufficiency, or facadeecal occult blood), prompting further diagnostic workup and supporting management of conditions such as inflammatory bowel disease (IBD), colorectal cancer, or pancreatic insufficiency via pharmacological treatment including biologics; 19.6% (904) of reports tested positive for multiple markers (microbiome and gastrointestinal), addressed via a personalised mix of pharmacological, nutritional and lifestyle modification strategies. These results demonstrate how the MetaXplore test provides critical new insights to enable clinicians to apply personalized, multi-dimensional treatment plans to support the clinical management of patients with chronic and functional lower gastrointestinal disorders. MetaXplore™? Patients Report Measurable Health Benefits: A separate study of 84 patients by Microba who received MetaXplore-guided care found that 65.5% reported health improvements after following their clinician's recommendations: 22.6% reported significant improvement; 42.9% noticed some improvement. These preliminary results highlight how the Meta Xplore test results and personalised, targeted interventions improve patient outcomes. This initial patient survey data demonstrates the relationship between MetaXplore positive test results and improved patient outcomes, supporting the clinical impact Microba is seeing with clinicians and patients, and setting up for larger planned studies measuring patient outcomes. MetaXplore™™? is supporting clinicians to manage and improve outcomes for these patients through a comprehensive test that can: Assess structural and functional abnormalities in the microbiome; Detect overlooked harmful gut bacteria (pathogens), inflammatory or insufficiency markers; Identify evidence based, personalised pharmacological, nutritional and lifestyle modifications strategies; Support patient motivation and adherence to pharmacological, nutritional and lifestyle modified; May support identification of cases where mental health support may be appropriate. As the burden of chronic digestive disorders continues to grow, MetaXplore offers a scalable, scalable, scalable, scalable, and support support support the clinical management of patients to manage and improve outcomes.